Dr. Stahl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-732-6089Fax+1 617-732-5706
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2018
Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017
Hannover Medical SchoolClass of 2012
Certifications & Licensure
MA State Medical License 2021 - 2026
CT State Medical License 2017 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 93 citationsThe use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres
Blood Advances. 2018-07-24 - 27 citationsImmunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic MicroenvironmentOlumide B. Gbolahan, Amer M. Zeidan, Maximilian Stahl, Mohammad Abu Zaid, Sherif S. Farag
International Journal of Molecular Sciences. 2017-07-31 - 109 citationsClinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao
Blood Advances. 2021-03-09
Lectures
- Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment UpdatesJune 1st, 2024- What Is the Best Method for Cytoreduction in Patients with Acute Myeloid Leukemia and Hyperleukocytosis?February 1st, 2021
Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)December 6th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
